SVT-23431

SVT-23431 is a topical ophthalmic non-steroidal anti-inflammatory drug (NSAID) being developed by Laboratorios Salvat for the management of inflammation and pain following ocular surgery. It is specifically formulated as a single-dose, preservative-free preparation to minimize the risk of corneal toxicity and ocular surface irritation often associated with preservatives like benzalkonium chloride. As an NSAID, its mechanism of action involves the inhibition of cyclooxygenase (COX) enzymes, which are responsible for the synthesis of prostaglandins that mediate inflammatory responses and pain signaling in ocular tissues. The drug is part of Salvat's pipeline focusing on drug delivery technologies and reformulations of established molecules to improve safety and patient compliance.